Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography–tandem mass spectrometry
- 1 November 2010
- journal article
- research article
- Published by Elsevier BV in Journal of Chromatography B
- Vol. 878 (29), 3033-3038
- https://doi.org/10.1016/j.jchromb.2010.08.049
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometryJournal of Chromatography B, 2009
- Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practiceJournal of Pharmaceutical and Biomedical Analysis, 2009
- SorafenibDrugs, 2009
- Development of a rapid and sensitive LC–MS/MS assay for the determination of sorafenib in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2008
- Potential role of sorafenib in the treatment of acute myeloid leukemiaLeukemia & Lymphoma, 2008
- A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assayJournal of Chromatography B, 2007
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokineticsCancer Chemotherapy and Pharmacology, 2005
- Factors Affecting Cytochrome P-450 3A Activity in Cancer PatientsClinical Cancer Research, 2004